11:16 AM
 | 
Oct 26, 2017
 |  BC Innovations  |  Emerging Company Profile

Taking RNA epigenetics by Storm

Storm is tapping the nascent field of RNA epigenetics for cancer

Storm Therapeutics Ltd. is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer.

CEO Keith Blundy told BioCentury RNA-modifying enzymes fit into the landscape of epigenetic targets because, like DNA-modifying enzymes, they alter gene expression without changing the genetic code.

"It's the same paradigm as DNA and histone modification enzymes that have been drugged by small molecules and compounds in the clinic," he said, adding that Storm is following a similar development path by starting in cancer.

Humans express at least 140 RNA-modifying enzymes, several of which were discovered by Storm's academic founders Tony Kouzarides and Eric Miska. The enzymes decorate both coding and non-coding RNAs with a variety of chemical moieties -- ranging from simple...

Read the full 624 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >